Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics

Varování

Publikace nespadá pod Lékařskou fakultu, ale pod Farmaceutickou fakultu. Oficiální stránka publikace je na webu muni.cz.

Autoři	FENG XJ SUREDA A JAFARI S MEMARIANI Z TEWARI D ANNUNZIATA G BARREA L HASSAN STS ŠMEJKAL Karel MALANÍK Milan SYCHROVÁ Alice BARRECA D ZIBERNA L MAHOMOODALLY MF ZENGIN G XU SW NABAVI SM SHEN AZ
Rok publikování	2019
Druh	Článek v odborném periodiku
Časopis / Zdroj	Theranostics
Fakulta / Pracoviště MU	Farmaceutická fakulta
Citace
Doi	http://dx.doi.org/10.7150/thno.30787
Klíčová slova	berberine; cardiovascular diseases; metabolic diseases; targets; therapeutics
Popis	Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.